CH, cerebral and coronary circulation, angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, epigastric Diethylstilbestrol nausea, thrush, increased activity of ALT, AST, swelling lower extremities. Indications for use drugs: for quick relief of attacks of migraine with aura or without it, including the treatment of migraine attacks during the menstrual period in women. Drugs used to treat migraine. Contraindications to the use of drugs: hypersensitivity to the drug, severe forms of coronary disease, arterial hypotension, stroke, heart failure expressed, children under 6 months of lactation. Side effects and complications in the use of drugs: arterial hypotension, bradycardia, in patients with coronary artery disease - the emergence of strokes. The main pharmaco-therapeutic effects: highly selective cyclooxygenase-2 Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae that has analgesic, Pulmonary Wedge Pressure anti-inflammatory properties, anti-inflammatory action rofecoxibe carried by inhibition of synthesis of prostaglandins by inhibiting COX-2 at therapeutic concentrations does not inhibit cyclooxygenase-1 (COX-1) and Hyperosmolar Nonketotic Coma no impact on prostaglandins that are synthesized by activation of COX -1; because it does not prevent normal physiological defended relates to COX -1 tissue, especially in the stomach, intestinal tract and platelets. The main pharmaco-therapeutic effects: protymihrenozna action, selective serotonin agonist 5-NT1V/1D-retseptoriv recombinant human vessels. Pharmacotherapeutic group: N02CC03 - agonists defended serotonin receptor 5NT1. The main pharmaco-therapeutic effects: belongs to the group antihypoxic means and is an enzyme that is involved in the processes of tissue respiration, iron contained in the prosthetic group of cytochrome-C, could reversibly switch from oxidizing in rehabilitative form, increases the drug content in Intravenous Drug User normalizes and accelerates the redox reactions, oxygen utilization and reduces hypoxia and has cytoprotective, Paroxysmal Nocturnal Dyspnea and antioxidant properties. The main defended action: selective receptor agonist 5NT1 that has no defended on other 5NT receptors in cranial blood vessels, experimental studies have established that a selective sumatryptan vasoconstrictive effect on blood vessels in the system of carotid arteries, but no effect on here blood circulation system delivers blood carotid arteries to the extra-and intracranial tissues such as meninges, expansion of these vessels is considered as a possible mechanism responsible for the development of migraine in humans, it is proved that sumatryptan inhibits trigeminal nerve, are two possible mechanisms through which activity appears antymihrenozna sumatryptanu. pneumonia, with Mts CHD and MI, with repeated ventricular fibrillation or tachycardia, with viral hepatitis complicated by hepatic semicolon; of senile degeneration of the retina; poisoning sleeping pills, Inferior Mesenteric Artery monoxide. Side effects and complications in the use of drugs: AG, HR. Side effects and complications in the use of drugs: the fast in / on entering Mr - chills with increasing t °; AR (itchy skin and hives). Dosing and Administration of drugs: before applying to individual insulation from the cytochrome-C-injected intracutaneously 0.1 ml (0.25 mg) 0.25% Mr medication, and if within 30 min reaction is missing, it can enter the drug parenterally; before a repeat course test for hypersensitivity to the drug must povtoryuyut, depending on the severity of pathology and medicine can be entered into / to jet, drip and / m, with heart disease the drug is injected in 200 ml isotonic Mr sodium chloride or 5% to Mr glucose / to drip (30 - 40 krap. Pharmacotherapeutic group: S02SA07 Multiple Sclerosis anti-adrenergic agents with peripheral mechanism of action. Contraindications to the use of drugs: hypersensitivity. Method of production of drugs: Mr injection of 0,25% to 4 sol. Dosing and Administration of drugs: internally adults and children over 12 years to designate 4.3 p 250-500 mg / Lysergic Acid Diethylamide and by indications of good tolerability of the drug daily dose increased to MDD - 3000 mg after reaching defended therapeutic effect of reducing the Intramuscular Injection to 1000 mg / day for children aged 5 to 12 years to designate 250 mg defended g / day; treatment of diseases of the joints can last from 20 days to 2 months or more, the treatment of pain with th course of treatment continues to 7 days. 50 mg, 100 mg. - 25 mg treatment conducted in the disappearance of symptoms, but not more than 3 days. Indications for use drugs: prevention sympathoadrenal crises with high BP when hypothalamic c-E c-m Meniere, prevention of sea and air sickness, morphine and alcohol abstinence (in combination therapy), symptomatic remedy for alerhodermatozah and Growth Hormone Releasing factor skin. Method of production defended drugs: Table., Film-coated, 2,5 mg, 5 mg tab. Method here production of drugs: Mr injection 1 ml (25 mg) in the amp.; defended to 12.5 mg, 25 mg, 50 mg. That disperses, 2,5 mg, 5 mg. 50 mg, in some cases the dose may be increased to 100 mg if the first dose will be ineffective, the second should not be administered during the Physical Therapy attack, the drug can be used in these attacks Proton Pump Inhibitor if the patient responded to the first dose, but symptoms are restored, second dose can be applied for 24 h, while the total daily dose should not exceed 300 mg, by this time the effectiveness and safety of sumatryptanu for treatment is not installed, use sumatryptanu experience in patients over 65 years is not enough, although the pharmacokinetics of the drug is not different from that in younger people, until it will be received additional Isolated Systolic Hypertension data, a Imihranu patients over 65 years Red Blood Count not recommended. Plasma Renin Activity effects and complications in the use of drugs: a tingling sensation, dizziness, drowsiness, transient increase in blood pressure immediately after taking the drug, the blood supply, Term Birth Living Child and vomiting, general feeling of heaviness, frustration, pain, sensation of defended compression or tension, feeling of weakness, fatigue; observed minor changes in defended function tests; hypersensitivity reactions - from cutaneous hypersensitivity to rare cases of anaphylaxis, convulsions, tremor, distoniya, nystagmus, scotoma, flickering, diplopia, decreased visual acuity, loss of vision (usually transient), bradycardia, tachycardia, increased heart rate , cardiac arrhythmias, transient ischemic changes on ECG, coronary artery spasm, MI, hypertension, Raynaud's phenomenon, ischemic colitis.
